

AstraZeneca sells European rights for heart failure treatment for \$210M

24 July 2018 | News

Cheplapharm would pay AstraZeneca \$200m on completion of the agreement, expected to be finalised in the third quarter of 2018, plus a time-bound payment of \$10m and sales-contingent milestones.



Singapore - AstraZeneca has agreed to sell the European commercial rights to hypertension and heart failure meds Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil/hydrochlorothiazide) to Cheplapharm Arzneimittel GmbH.

AZN will continue to manufacture and supply the products under a supply agreement and will continue to commercialize both in all markets where it retains rights.

Under the terms of the agreement, AZN will receive \$200M, a time-bound payment of \$10M and sales-related milestones. The deal should close this quarter.